JP2023553561A5 - - Google Patents
Info
- Publication number
- JP2023553561A5 JP2023553561A5 JP2023536095A JP2023536095A JP2023553561A5 JP 2023553561 A5 JP2023553561 A5 JP 2023553561A5 JP 2023536095 A JP2023536095 A JP 2023536095A JP 2023536095 A JP2023536095 A JP 2023536095A JP 2023553561 A5 JP2023553561 A5 JP 2023553561A5
- Authority
- JP
- Japan
- Prior art keywords
- glp
- approximately
- composition according
- concentration
- cresol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20214562 | 2020-12-16 | ||
| EP20214562.9 | 2020-12-16 | ||
| PCT/EP2021/086147 WO2022129311A1 (en) | 2020-12-16 | 2021-12-16 | Pharmaceutical composition of glp-1/glp-2 dual agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023553561A JP2023553561A (ja) | 2023-12-22 |
| JP2023553561A5 true JP2023553561A5 (https=) | 2024-12-23 |
| JP7809117B2 JP7809117B2 (ja) | 2026-01-30 |
Family
ID=74141274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536095A Active JP7809117B2 (ja) | 2020-12-16 | 2021-12-16 | Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240024425A1 (https=) |
| EP (1) | EP4262745B1 (https=) |
| JP (1) | JP7809117B2 (https=) |
| KR (1) | KR20230121823A (https=) |
| CN (1) | CN116710114B9 (https=) |
| AU (1) | AU2021404497A1 (https=) |
| CA (1) | CA3200526A1 (https=) |
| CL (1) | CL2023001747A1 (https=) |
| ES (1) | ES3019509T3 (https=) |
| IL (1) | IL301893A (https=) |
| MX (1) | MX2023006284A (https=) |
| WO (1) | WO2022129311A1 (https=) |
| ZA (1) | ZA202304235B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202111311WA (en) | 2019-06-14 | 2021-12-30 | Zealand Pharma As | Pharmaceutical parenteral composition of dual glp1/2 agonist |
| IL301892A (en) * | 2020-12-16 | 2023-06-01 | Zealand Pharma As | Drug composition of dual GLP-1/GLP-2 agonists |
| JP2024533153A (ja) * | 2021-09-03 | 2024-09-12 | ジーランド ファーマ エー／エス | 投薬レジーム |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU723268B2 (en) | 1996-09-09 | 2000-08-24 | Zealand Pharma A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
| MXPA04003569A (es) * | 2001-10-19 | 2004-07-23 | Lilly Co Eli | Mezclas bifasicas de glp-1 e insulina. |
| ES2373660T3 (es) | 2003-11-13 | 2012-02-07 | Novo Nordisk A/S | Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo. |
| CN104902922B (zh) * | 2012-11-13 | 2017-12-12 | 阿道恰公司 | 包含经取代阴离子化合物的速效胰岛素制剂 |
| CN103893744B (zh) * | 2012-12-24 | 2017-12-19 | 杭州九源基因工程有限公司 | 一种治疗糖尿病的药物制剂及其制备方法 |
| AR110300A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| EP3551651B1 (en) * | 2016-12-09 | 2024-03-06 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| SG11202111311WA (en) * | 2019-06-14 | 2021-12-30 | Zealand Pharma As | Pharmaceutical parenteral composition of dual glp1/2 agonist |
-
2021
- 2021-12-16 CA CA3200526A patent/CA3200526A1/en active Pending
- 2021-12-16 JP JP2023536095A patent/JP7809117B2/ja active Active
- 2021-12-16 US US18/039,857 patent/US20240024425A1/en active Pending
- 2021-12-16 MX MX2023006284A patent/MX2023006284A/es unknown
- 2021-12-16 WO PCT/EP2021/086147 patent/WO2022129311A1/en not_active Ceased
- 2021-12-16 CN CN202180080845.4A patent/CN116710114B9/zh active Active
- 2021-12-16 ES ES21836185T patent/ES3019509T3/es active Active
- 2021-12-16 IL IL301893A patent/IL301893A/en unknown
- 2021-12-16 KR KR1020237023812A patent/KR20230121823A/ko active Pending
- 2021-12-16 EP EP21836185.5A patent/EP4262745B1/en active Active
- 2021-12-16 AU AU2021404497A patent/AU2021404497A1/en active Pending
-
2023
- 2023-04-06 ZA ZA2023/04235A patent/ZA202304235B/en unknown
- 2023-06-14 CL CL2023001747A patent/CL2023001747A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023553561A5 (https=) | ||
| JP2023553563A5 (https=) | ||
| JP5669395B2 (ja) | 新規化合物および摂食行動に対するその効果 | |
| US11001619B2 (en) | GIP agonist compounds and methods | |
| RU2012128547A (ru) | Дважды ацилированные производные glp-1 | |
| RU2017101333A (ru) | Новые аналоги глюкагона | |
| RU2019121253A (ru) | Ацилированные двойные агонисты glp-1/glp-2 | |
| ES2976562T3 (es) | Derivado del glucagón | |
| US20180280480A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| RU2019121280A (ru) | Glp-1/glp-2 двойные агонисты | |
| US20200392197A1 (en) | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | |
| JP2023545684A5 (https=) | ||
| RU2020109881A (ru) | Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита | |
| ES2973935T3 (es) | Triple agonista que tiene actividad con respecto a todos los receptores de glucagón, GLP-1 y GIP para el tratamiento de enfermedad hepática | |
| RU2006115916A (ru) | Комбинированная терапия hcv инфекции | |
| JP2021511296A5 (https=) | ||
| TW201105336A (en) | Combined medicine of pyrazole derivative and biguanide drug | |
| JP2015517458A5 (https=) | ||
| JP2024533153A5 (https=) | ||
| CN101578107B (zh) | 泌酸调节肽类似物及其对进食行为的影响 | |
| JP2024514352A5 (https=) | ||
| JP2025178483A (ja) | ポリペプチドを含む医薬組成物 | |
| JP2012523434A5 (https=) | ||
| IL315941A (en) | Uses of farnesoid x receptor agonists | |
| RU2021139206A (ru) | Фармацевтическая парентеральная композиция двойного агониста glp1/2 |